drugset / Trial / NCT02724904
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
Phase 1/2
Withdrawn
Massachusetts General Hospital
Adienne SA · collabDana-Farber Cancer Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is assessing the feasibility of reduced intensity allogeneic hematopoietic stem cell transplantation (HSCT) as a possible treatment for relapsed / refractory non-Hodgkin lymphoma involving the central nervous system (CNS). HSCT is the transplantation of stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood.
Timeline
- Start
- 2017-05
- Primary completion
- 2019-12
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Fludarabine | Small molecule | — | — |
| Background | Methotrexate | Small molecule | — | Intravenous |
| Background | Thiotepa | Other / unclassified | — | — |